FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251193984> ?p ?o ?g. }

• W4251193984 endingPage "489" @default.
• W4251193984 startingPage "489" @default.
• W4251193984 abstract "What's in a name? When it comes to psychotropic drugs, a lot. For doctors, a second-generation antipsychotic might sound like a newer, better, more advanced option. For patients who have finally summoned the courage to seek help for an anxiety disorder, being prescribed an antidepressant might suggest that the doctor wasn't listening to them and dishes out happy pills to everyone. People prescribed an antipsychotic for depression might legitimately be concerned that their psychiatrist, without telling them, believes they have a psychotic disorder. For decades, the taxonomy for psychotropic medications has been based on indication, with some molecular structure or receptor function thrown in. Some antidepressants are named after their structure, such as tricyclic antidepressants, and some by their function, such as selective serotonin reuptake inhibitors. Antipsychotic classifications of typical and atypical, or first and second generation, provide no clues as to how they might work. Many terminologies were coined when there was only one known indication for a particular medication, so it made sense to classify them as an anxiolytic or an antipsychotic, whereas today we know that one drug may have many uses and that symptoms overlap between conditions. Current psychotropic nomenclature does little to help rational prescribing practices or aid patient psychoeducation. Is it time to change? Many leading psychopharmacologists think it is. To bring about a change in terminology requires a concerted and coordinated response across the medical community, which is now being called for. After almost a decade of collaboration between the European, American, Asian, and International Colleges of Neuropsychopharmacology, and the International Union of Basic and Clinical Pharmacology, the new Neuroscience-based Nomenclature (NbN) proposes to change the way we describe psychotropics. The aim is to reflect their pharmacological properties, rather than the mental health conditions that they are usually used to treat. The NbN includes 108 compounds, which represents most available psychotropics, and classifies them into 11 pharmacological domains, with ten modes of action. It is recognised that some compounds will have more than one mode of action. Pharmacological domains reflect our understanding of which neurotransmitter systems are modified by the drug in question, whether it be acetylcholine, histamine, or serotonin; modes of action define whether the drug is a receptor agonist or antagonist, or an enzyme inhibitor. The NbN aims to provide a rationale for the use of particular medications, to help clinicians determine the next logical step in prescribing, and to be future-proof, with room to add new drugs as they are licensed. Changing language and habits formed over decades will be a long process. Journals, including The Lancet Psychiatry, should consider these proposals carefully; the NbN's free glossary app helps to translate former descriptions of psychotropics to NbN terms. But is it worth it? There will doubtless be hitches on the way from translating old terminology to NbN terms. Working out gaps in the evidence base and directions for future research relies on carrying out thorough systematic reviews: work published before NbN will use old terminology and require searching under possible indication, chemical structure, and functional properties, and there will inevitably be a time period during which doctors will need to be able to use both old and new names. It is unlikely that anything can be truly future-proof, and advances in translational neuroscience might render parts of the newly carefully translated app as arbitrary as a description of a third-generation drug. There is also the danger that rather than leading to more rational prescribing, the use of NbN could have the opposite effect, and lead to people being given unnecessary and excessive medications; for example, prescription of a “dopamine receptor antagonist” might be easier to justify to patients than an “antipsychotic”. Particularly in psychiatry, however, where there has been a lack of targeted therapeutics for a long time and the use of language often suffers from a similar lack of precision, changing names to reflect contemporary pharmacological knowledge and specific underlying neuroscience is important. A new language is not in itself sufficient to change practice, and needs to be accompanied by the actions that should naturally lead from it—namely, a trans-diagnostic approach and commitment to updating the new nomenclature; rational prescribing practices; and better communication with patients about the rationale for use of medications. The desire to cling to established nomenclature is understandable. But to do so risks using an outdated map to navigate new and complex territory. Please write or tweet @TheLancetPsych to tell us what you think. Neuroscience-based nomenclature (NbN)The existing nomenclature for psychotropic drugs is based on WHO's Anatomical-Therapeutic-Chemical (ACT) classification system, which was established in the 1960s. Perhaps unsurprisingly, this system has its flaws. The system traditionally classifies psychotropic drugs by indication, such as antidepressants for depression; however, psychotropic drugs can nowadays be prescribed for more than one purpose, such as antidepressants being prescribed for anxiety. This mismatch between the existing terminology of the drug and the disorder for which it is prescribed can cause patients to doubt the drug's effectiveness, which can in turn affect adherence. Full-Text PDF" @default.
• W4251193984 created "2022-05-12" @default.
• W4251193984 creator A5002324805 @default.
• W4251193984 date "2016-06-01" @default.
• W4251193984 modified "2023-09-27" @default.
• W4251193984 title "Naming names" @default.
• W4251193984 doi "https://doi.org/10.1016/s2215-0366(16)30072-4" @default.
• W4251193984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27262036" @default.
• W4251193984 hasPublicationYear "2016" @default.
• W4251193984 type Work @default.
• W4251193984 citedByCount "2" @default.
• W4251193984 countsByYear W42511939842017 @default.
• W4251193984 countsByYear W42511939842023 @default.
• W4251193984 crossrefType "journal-article" @default.
• W4251193984 hasAuthorship W4251193984A5002324805 @default.
• W4251193984 hasConcept C118552586 @default.
• W4251193984 hasConcept C138885662 @default.
• W4251193984 hasConcept C15744967 @default.
• W4251193984 hasConcept C2776412080 @default.
• W4251193984 hasConcept C2778271842 @default.
• W4251193984 hasConcept C2780494398 @default.
• W4251193984 hasConcept C2781419993 @default.
• W4251193984 hasConcept C41895202 @default.
• W4251193984 hasConcept C547195049 @default.
• W4251193984 hasConcept C558461103 @default.
• W4251193984 hasConcept C71924100 @default.
• W4251193984 hasConceptScore W4251193984C118552586 @default.
• W4251193984 hasConceptScore W4251193984C138885662 @default.
• W4251193984 hasConceptScore W4251193984C15744967 @default.
• W4251193984 hasConceptScore W4251193984C2776412080 @default.
• W4251193984 hasConceptScore W4251193984C2778271842 @default.
• W4251193984 hasConceptScore W4251193984C2780494398 @default.
• W4251193984 hasConceptScore W4251193984C2781419993 @default.
• W4251193984 hasConceptScore W4251193984C41895202 @default.
• W4251193984 hasConceptScore W4251193984C547195049 @default.
• W4251193984 hasConceptScore W4251193984C558461103 @default.
• W4251193984 hasConceptScore W4251193984C71924100 @default.
• W4251193984 hasIssue "6" @default.
• W4251193984 hasLocation W42511939841 @default.
• W4251193984 hasLocation W42511939842 @default.
• W4251193984 hasOpenAccess W4251193984 @default.
• W4251193984 hasPrimaryLocation W42511939841 @default.
• W4251193984 hasRelatedWork W176593424 @default.
• W4251193984 hasRelatedWork W2072731221 @default.
• W4251193984 hasRelatedWork W2144066144 @default.
• W4251193984 hasRelatedWork W2165343866 @default.
• W4251193984 hasRelatedWork W2296147370 @default.
• W4251193984 hasRelatedWork W2326629460 @default.
• W4251193984 hasRelatedWork W2748952813 @default.
• W4251193984 hasRelatedWork W2899084033 @default.
• W4251193984 hasRelatedWork W4363678612 @default.
• W4251193984 hasRelatedWork W2131223004 @default.
• W4251193984 hasVolume "3" @default.
• W4251193984 isParatext "false" @default.
• W4251193984 isRetracted "false" @default.
• W4251193984 workType "article" @default.